First Volunteer Receives Lassa Fever Vaccine in Oxford Trial

The Oxford Vaccine Group has initiated a groundbreaking trial by vaccinating the first volunteer in a human study of a Lassa fever vaccine. This trial, supported by the Coalition for Epidemic Preparedness Innovations (CEPI), marks a critical step in addressing a disease identified by the World Health Organization (WHO) as a priority pathogen due to its potential to cause significant public health threats.

Trial Details and Significance

The trial, known as VITAL01, is being conducted in Oxford, with plans for a second phase of the study set to commence in Ghana in early 2024. A total of 31 participants, aged between 18 and 55, will take part in this important research, which aims to evaluate the vaccine’s safety and immune response.

Lassa fever, caused by the Lassa virus, is primarily transmitted through contact with the urine or feces of infected rodents. The disease can lead to severe health complications, including hearing loss, significant bleeding, and potentially death. First identified in Nigeria during the late 1960s, Lassa fever remains endemic in West Africa, posing a risk to millions. According to estimates, by 2070, as many as 700 million people could live in regions vulnerable to Lassa fever, highlighting the urgent need for effective preventive measures.

Vaccine Development and Expert Insights

The innovative vaccine was developed by researchers at the Pandemic Sciences Institute at the University of Oxford. It utilizes the same viral vector platform as the Oxford/AstraZeneca COVID-19 vaccine, which is credited with saving approximately 6 million lives in its first year of use.

Professor Maheshi Ramasamy, the Chief Investigator for the trial, emphasized the importance of vaccines in global health. In a statement, she said, “Vaccines are one of the most powerful tools we have in global health: they save lives, stop outbreaks, and strengthen health systems. We’re delighted to start the VITAL01 Lassa fever vaccine study here in Oxford.”

Ramasamy further noted, “Building on Oxford’s world-leading experience in developing vaccines for emerging infections and pandemics, including COVID-19, this study is a crucial step toward protecting vulnerable communities from the devastating impact of Lassa fever.”

The efforts to advance a Lassa vaccine to licensure are being coordinated by the Lassa fever Coalition, which comprises West African leaders and public health experts, along with support from CEPI. This consortium is working alongside vaccine manufacturers to facilitate the development and equitable introduction of Lassa fever vaccines in the affected regions.

The commencement of this trial represents not only a significant scientific milestone but also a hopeful advancement in the fight against a disease that has long posed a threat to public health in endemic areas.